Abstract:
The live microorganism industry is rapidly growing, producing probiotics and
live biotherapeutic products (LBPs) designed to deliver health benefits. Ensuring these
products contain viable, strain-specific microorganisms at effective levels is essential, but
accurately measuring viability and potency remains challenging.
